Ed joined +ND Capital in 2017. He also serves as CEO and Chairman for a US-based ADME-TOX company and as a scientific and strategic advisor and BOD member to multiple companies where he is focused on building breakthrough nutritional and biologics therapies and diagnostics for health management. He has over 30 years of experience managing research in the biotechnology and pharmaceutical industries. He previously served as founding director of the Nestle Institute of Health Sciences, and CSO of ViaCyte and Modex Therapeutics. Prior to Modex, Ed held management and research positions at CytoTherapeutics and Bristol-Myers Squibb Co.